AbCellera Biologics ABCL
AbCellera Biologics reported a $40.76 million net loss
AbCellera Biologics (ABCL) filed a 10-Q with the SEC on Nov 9, 2026, 4:34 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001703057-26-000059
- Revenue of $10.64 million for Q3 2026
- Diluted EPS of -$0.13 for Q3 2026
- Cash and equivalents of $163.8 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
1 new risk factor · 2 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $10.64M | $4.05M | +163% |
| Operating income and margin | −$53.32M · -501.1% | −$62.78M · -1550% | +15%, margin +1048.9 pts |
| Net income | −$40.76M | −$55.43M | +27% |
| Operating cash flow | $26.91M | $25.92M | +3.8% |
| Cash | $163.8M | $120.07M | +36% |
New risk factors (1)
- Sales of a substantial number of our common shares in the public market could occur at any time. Certain institutional investors hold a substantial percentage of our outstanding common shares. If our shareholders sell, or the market perceives that our shareholders intend to sell, substantial amounts of our common…
Removed risk factors (2)
- Sales of a substantial number of our common shares in the public market could occur at any time. If our shareholders sell, or the market perceives that our shareholders intend to sell, substantial amounts of our common shares in the public market, the market price of our common shares could decline significantly.
- Additionally, certain holders of our common shares have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other shareholders. If we were to register the resale of…